Clinical trialsCompany release

Remix's oral MYB degrader REM-422 shows responses in 4 of 7 biomarker-positive ACC patients

🇺🇸 Passage BIO, Inc. (PASG) · Thu 19 Nov 2026

Late-breaking Phase 1 data at 24 mg, the recommended Phase 2 dose, show a 57% response rate in biomarker-positive adenoid cystic carcinoma, with no dose-limiting toxicities reported.

Remix Therapeutics presented updated Phase 1 results for REM-422 on 19 November 2026 as a late-breaking abstract at the EORTC-NCI-AACR Symposium. REM-422 is an oral MYB mRNA degrader. The data come from the Phase 1 part of the ARIA Phase 1/2 study in recurrent or metastatic adenoid cystic carcinoma (ACC).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Passage BIO, Inc. ↗

Article written by VigiEye from the official source (Passage BIO, Inc.). Claims are the company's own. AI-assisted; check the source before acting.